MANIFEST: Multiomic Platform for Cancer Immunotherapy

Cancer Discov. 2025 May 2;15(5):878-883. doi: 10.1158/2159-8290.CD-25-0099.

Abstract

Immunotherapy has revolutionized survival outcomes for many patients diagnosed with cancer. However, biomarkers that can reliably distinguish treatment responders from nonresponders, predict potential life-threatening and life-changing drug-induced toxicities, or rationalize treatment choices are still lacking. In response to this unmet clinical need, we introduce Multiomic ANalysis of Immunotherapy Features Evidencing Success and Toxicity, a tumor type-agnostic platform to provide deep profiling of patients receiving immunotherapy that will enable integrative identification of biomarkers and discovery of novel targets using artificial intelligence and machine learning.

MeSH terms

  • Biomarkers, Tumor
  • Humans
  • Immunotherapy* / methods
  • Machine Learning
  • Neoplasms* / genetics
  • Neoplasms* / immunology
  • Neoplasms* / therapy

Substances

  • Biomarkers, Tumor